Prediction Models for Radiation-Induced Neurocognitive Decline in Adult Patients with Primary or Secondary Brain Tumors: A Systematic Review

Fariba Tohidinezhad (fariba.tohidinezhad@maastro.nl)  
Maastricht University Medical Centre+: Maastricht Universitair Medisch Centrum+  
https://orcid.org/0000-0001-8880-3593

Dario Di Perri  
Cliniques Universitaires Saint-Luc

Catharina M.L. Zegers  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Jeanette Dijkstra  
Maastricht University Medical Centre+: Maastricht Universitair Medisch Centrum+

Monique Anten  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Andre Dekker  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Wouter Van Elmpt  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Daniëlle BP Eekers  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+

Alberto Traverso  
Maastricht UMC+: Maastricht Universitair Medisch Centrum+  
https://orcid.org/0000-0001-6183-4429

Research Article

Keywords: Cranial Irradiation, Cognitive Dysfunction, Neurotoxicity, Machine Learning

Posted Date: December 14th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1151996/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Purpose:** Although an increasing body of literature suggests a relationship between brain irradiation and deterioration of neurocognitive function, it remains as the standard therapeutic and prophylactic modality in patients with brain tumors. This review was aimed to abstract and evaluate the prediction models for radiation-induced neurocognitive decline in patients with primary or secondary brain tumors.

**Methods:** MEDLINE was searched on October 31, 2021 for publications containing relevant truncation and MeSH terms related to "radiotherapy", "brain", "prediction model", and "neurocognitive impairments". Risk of bias was assessed using the Prediction model Risk Of Bias ASsessment Tool.

**Results:** Of 3,580 studies reviewed, 23 prediction models were identified. Age, tumor location, education level, baseline neurocognitive score, and radiation dose to the hippocampus were the most common predictors in the models. The Hopkins verbal learning (n=7) and the trail making tests (n=4) were the most frequent outcome assessment tools. All studies used regression (n=14 linear, n=8 logistic, and n=4 Cox) as machine learning method. All models were judged to have a high risk of bias mainly due to issues in the analysis.

**Conclusion:** Existing models have limited quality and are at high risk of bias. Following recommendations are outlined in this review to improve future models: develop a standardized instrument for neurocognitive assessment in patients with brain tumors; adherence to model development and validation guidelines; careful choice of candidate predictors according to the literature and domain expert consensus; and considering radiation dose to brain substructures as they can provide important information on specific neurocognitive impairments.

Introduction

Brain tumors refers to two general types: primary malignant tumors accounting for 1% of the newly diagnosed cancer patients and secondary/metastatic brain tumors occurring in 20% of the cancer patients [1, 2]. Patients with primary or metastatic brain tumors are characterized by complex and sometimes severe symptoms, usually associated with poor prognosis. Radiation Therapy (RT) is an indispensable therapeutic and prophylactic component for extending patient survival as well as effective symptom relief [3]. Depending on the location of the tumor, the use of brain RT has been confounded by the challenge of damaging critical vascular and neural structures. Patients treated with RT to the brain might experience acute irradiation triggered inflammation and be at risk for late toxicity sequelae [4]. One of the possible side effects of RT is neurocognitive decline.

Neurocognitive decline is a progressive and often disabling side effect reported in 50-90% of the patients who receive whole brain irradiation [5]. The literature suggests that radiation-induced neurocognitive decline includes damage in multiple neural cell types, increasing neuroinflammation, reducing neurogenesis in the hippocampus, and causing functional and structural alterations in the brain blood vessels [6]. Major neurocognitive deficits including, dysfunctions related to learning, attention, memory, processing speed, spatial processing, and executive capabilities may become manifest from months to years after irradiation [7, 8]. Improvements in radiation delivery technologies (e.g., stereotactic radiotherapy, intensity modulated radiotherapy, and proton beam therapy) allow reducing the dose delivered to the normal brain tissue [9, 10]. Identification of the patients who might benefit from a certain treatment, will increase efficacy and potentially reduce costs.

Clinical modelling refers to the use of mathematical equations to support physicians in proposing individualized treatment indications [11]. Although medical literature overflows with articles offering to help clinicians and patients in decision making, front-line clinical use of the available prediction models remain underutilized mainly due to lack of adherence to model development and evaluation guidelines [12]. The following considerations are crucial to build a reliable prediction model: obtaining high quality multidimensional data from patients who represent the intended target population, including easy-to-use predictors which have been measured without knowledge of the outcome data, using standard outcome definition with reasonable time interval since predictor assessment, and handling statistical concerns and complexities during analysis with appropriate performance assessment [13].

Previous reviews in recent years have attempted to describe the mechanisms, impact size, and therapeutic implications of the radiation-induced neurocognitive decline in human and preclinical studies [5, 14, 15]. In this review, we aim to: 1) identify the prediction models for radiation-induced neurocognitive decline, 2) abstract candidate and significant predictors, and 3) discuss the quality and applicability of available models in clinical practice.

Methods

**Search strategy**

The MEDLINE database was searched systematically to identify relevant English articles published from inception to October 31, 2021. The search strategy consisted of a combination of subject mesh terms and truncation of free words. To identify the prediction model studies, a broader version of the previously validated search strategy published by Geersing et al. [16] was combined with the terms related to "radiotherapy", "brain", and "neurocognitive impairments" (full search string provided in Supplementary Material S1). In addition, a manual search was conducted on references of the included articles. This review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Selection of eligible studies**

Studies were included if they reported the development or external validation of at least one multivariable prediction model for specific or general neurocognitive deficit in adult patients who received either therapeutic or prophylactic brain irradiation for primary or metastatic brain tumors. Two independent reviewers (FT and DDP) performed the title/abstract and full-text screening using the following exclusion criteria: 1) lack of model's specifications, 2) no significant predictors in multivariate analysis, 3) univariate associations, 4) preclinical studies, 5) editorials, letters, conference abstracts, or non-original studies, or 6) no available full text. Disagreement between reviewers was resolved by consensus.
Data extraction

One reviewer extracted the data using a standard form designed according to the recommendation in the CHARMS statement [17]. Extracted data included information about publication year, data source, sample size, characteristics of the study population (country, age, gender), type of primary tumor, treatment-related parameters (surgery, chemotherapy, irradiation technique, prophylactic intention), and outcome (definition, measuring instrument, and time of assessment). Moreover, the following information was extracted to assess the methodological considerations: modeling technique, event per predictor, candidate predictors, effect estimates of the included predictors, model's intercept, and predictive performance measures (discrimination and calibration indices). A subsample of the extracted data (20%) was checked for correctness and completeness.

Quality assessment of included studies

The Prediction model Risk Of Bias ASsessment Tool (PROBAST) was used to assess the Risk Of Bias (ROB) of the identified prediction models [18]. PROBAST uses 20 signaling questions to cover the four key aspects of the ROB in prediction studies (i.e., participants, predictors, outcome, and analysis). Each signaling question is answered as "yes", "probably yes", "no", "probably no", or "no information" and each domain is judged as "low risk", "high risk", or "unclear" based on the signaling questions in each domain. The overall ROB is rated as low risk (all domains are judged as low risk), high risk (at least one domain is judged as high risk), or unclear (at least one domain is judged as unclear and the remaining domains are judged as low risk). The applicability of prediction models to the review question was also judged as "low risk", "high risk", or "unclear" in terms of participants, predictors, and outcome.

Results

General characteristics of included studies

The study selection process is shown in Figure 1. A total of 3,580 articles were retrieved. A total of 129 studies were retained for the full-text review after title/abstract screening. We further excluded 106 publications based on the exclusion criteria. Finally, 23 studies describing the development of prediction models were included, of which 16 [19–34] studies included patients with primary and 7 [35–41] with metastatic brain tumors. No external validation studies were identified.

As shown in Table 1, studies were published between 1996 and 2021, gradually increasing over the past few years. The prediction models were mainly developed in the United States (n=13, 56.5%) [22, 24–26, 28–30, 32, 35, 36, 39–41], Netherlands (n=3, 13%) [21, 23, 33], and Japan (n=2, 8.7%) [37, 38]. The median age of the study samples was 55 (IQR=48-61) with median 54% (IQR=45%-60%) male gender. Only one study included elderly (age 70-79) and very elderly patients (age≥80) with brain metastasis [39].
| Study                  | Year | Country | Sample Size | Primary tumor type | Outcome | Follow-up | Coefficient | Prediction Equation | Model Evaluation |
|------------------------|------|---------|-------------|-------------------|---------|-----------|-------------|--------------------|------------------|
| **Primary brain or head & neck tumors** |      |         |             |                   |         |           |             |                    |                  |
| Gregor et al. [19]     | 1996 | UK      | 30          | Gliomas           | NART, WAIS | >4 years | OR          | (WBRT vs. Focused RT ×7.1)* | -                |
| Blay et al. [20]       | 1998 | France  | 226         | Cerebral lymphomas| Neuroimaging | 76 months | RR          | (RT+chemotherapy×11.5)* | -                |
| Klein et al. [21]      | 2002 | Netherlands | 295     | Gliomas           | SCWT     | 12 years | RR          | (Antiepileptic×5.79)+ (tumor lateralization×5.3)* | -                |
| Kaleita et al. [22]    | 2004 | USA     | 79          | Brain tumors      | TMT-A    | NR        | Beta        | 3.932+(frontal×1.005)+(GBM×-0.812)+(Age 36-59×-1.174) | -                |
| Van Beek et al. [23]   | 2007 | Netherlands | 81      | Pituitary Adenoma | SF-36    | 10 years | Beta        | (Radiotherapy×0.56)+(male×0.48)+(intact HPA axis×0.57)* | -                |
| Wang et al. [24]       | 2010 | USA     | 299         | Oligodendrogliomas| MMSE     | 6.9 year | Beta        | (Assessment time×-0.013)+(KPS 80-100×2.724)+(age <50×1.41)* | -                |
| Starke et al. [25]     | 2011 | USA     | 152         | Meningioma        | Neuroimaging | 7 years  | OR          | (Tumor location clival/petrous×4)* | -                |
| Gondi et al. [26]      | 2012 | USA     | 29          | Brain tumors      | WMS III WL | 18 months | OR          | (D40% of hippocampus×7.3 Gy×19.3)* | -                |
| Kangas et al. [27]     | 2012 | Australia | 65       | Brain tumors      | FACT-G   | 3.5 months | Beta        | (Malignant×0.23)+(baseline PCL-S×0.31)+(baseline FACT-G×Brain×0.76)+(baseline POMS depression×0.46)* | -                |
| Chapman et al. [28]    | 2016 | USA     | 27          | Brain tumors      | HVLT-PR   | 18 months | Beta        | (Baseline HVLT-R×0.62)+(frontotemporal×2.19)+(age×-0.06)* | -                |
| Wong et al. [29]       | 2019 | USA     | 198         | Brain tumors      | DS, HVLT-R, COWA, TMT | 6 months | OR          | (Fatigue×1.05)* | -                |
| Gui et al. [30]        | 2020 | USA     | 30          | GBM               | HVLT-R DR | 36.1 months | Beta        | (Mean dose to ipsilateral hippocampus×-0.064)+(mean dose to bilateral hippocampus×-0.084)+(mean dose to ipsilateral SVZ×-0.089)+(mean dose to bilateral SVZ×-0.13)* | -                |
| Dutz et al. [31]       | 2020 | Germany | 62          | Brain tumors      | MoCA     | 2 years   | Beta        | -1.16+(Left laterality×2.37)+(cerebellum anterior V30Gy×5.14)+(cerebellum anterior V40Gy×6.85) | -                |
| Tibbs et al. [32]      | 2020 | USA     | 54          | Brain tumors      | DKEFS-TMT | 12 months | Beta        | (Beck anxiety inventories×0.425)* | -                |
| Zamanipoor et al. [33] | 2021 | Netherlands | 190     | Meningioma        | DS, AVLT, CWFT, CST, MCT, SCWT | 9 years  | OR          | (Age×1.024)+(tumor size before last intervention ×1.022)+(second resection×2.662)+(radiotherapy×2.819)+(educational level×0.359)+(years since diagnosis×1.130)* | AUC: 0.71 |
| Langegard et al. [34]  | 2021 | Sweden  | 266         | Brain tumors      | QIQ-BN20 | 1-3 months | Beta        | (Living alone×3.97)+(SCQ> 4 points×6.71)* | -                |
| **Secondary brain tumors** |      |         |             |                   |         |           |             |                    |                  |
| Wolfson et al. [35]    | 2011 | USA     | 75          | Lung              | HVLT, COWAT, TMT-A, TMT-B | 25.3 months | OR          | (Treatment type 2 Gy×18×8)+(treatment type 1.5 Gy×24×4.37)+(age×-1.12)+(education level ≤High school×2.96)* | -                |
### Variables in the prediction models

Figure 2 presents candidate and significant predictors in the models. All variables of 23 prediction models were easily obtainable (via medical records, radiotherapy planning systems, and questionnaires), including socio-demographic, baseline comorbidities and neurocognitive functions, tumor-related variables, medication use history, and treatment-related parameters (radiotherapy, chemotherapy, and surgery). Age was the most common candidate predictor and was considered in 11 (48%) prediction models followed by duration of follow-up (n=8, 35%), tumor type (n=5, 22%), tumor location (n=5, 22%), size/volume of brain tumor(s) (n=5, 22%), and use of radiotherapy (n=5, 22%).

The following variables were the most frequent significant predictors which remained in the models after multivariate analysis: age (n=7, 30%), tumor location (n=5, 22%), education level (n=3, 13%), baseline neurocognitive score (n=3, 13%), and radiation dose to the hippocampus (n=3, 13%). The median number of significant predictors in prediction models was 2 (IQR=1-3).

### Abbreviations (alphabetic order):
- AUC, Area Under the Receiver Operating Characteristic Curve
- AVLT, Auditory Verbal Learning Test
- COWAT, Controlled Oral Word Association Test
- CST, Concept Shifting Test
- CTCAE, Common Terminology Criteria for Adverse Events
- CWFT, Categoric Word Fluency Test
- D40%, equivalent dose in 2-Gy fractions (EQD2) assuming a/b=2 Gy to 40% of the structure volume
- DKFZ-TMT, Delis-Kaplan Executive Function System-Trail Making Test
- DS, Digital Span
- FACT-G, Functional Assessment of Cancer Therapy-General
- GBM, Glioblastoma Multiforme
- HA-WBRT, Hippocampal Avoidance-Whole-Brain Radiotherapy
- HPA, Hypothalamic Pituitary Adrenal
- HR, Hazard Ratio
- HVLT-DR, Hopkins Verbal Learning Test-Percent Retained
- HVLT-R, Hopkins Verbal Learning Test-Revised
- HVLT-R DR, HVLT-R Delayed Recall
- HVLT-R IR, HVLT-R Immediate Recall
- ICD-9-CM, International Classification of Diseases 9th Clinical Modification
- KPS, Karnofsky Performance Scale
- MCT, Memory Comparison Test
- MMSE, Mini Mental Status Examination
- MoCA, Montreal Cognitive Assessment
- NART, National Adult Reading Test
- OR, Odds Ratio
- PCL-S, Posttraumatic stress disorder Checklist-Stressor
- POMS, Profile of Mood States
- QLQ-BN20, Quality of Life Questionnaire-Brain Neoplasm20
- RT, Radiotherapy
- RTOG, Radiation Therapy Oncology Group
- SCQ, Self-Administered Comorbidity Questionnaire
- SCWT, Stroop color-word test
- SF-36, Short Form 36 Health Survey Questionnaire
- SVZ, Sub-Ventricular Zones
- TMT-A, Trail Making Test
- UK, United Kingdom
- USA, United States of America
- WAIS, Weschler Adult Intelligence Scale
- WBRT, Whole-Brain Radiotherapy
- WMS III WL, Wechsler Memory Scale-III Word List
- * The intercept of the model is not reported.
While radiation dose to the whole brain was removed from multivariate analysis in two prediction models [30, 38], dose to brain substructures, including hippocampus (n=3) [26, 30, 41], subventricular zone (n=1) [30], and cerebellum (n=1) [31] remained significant in the prediction models.

Outcome assessment

The following tests were the most common instruments used for measuring the neurocognitive decline: Hopkins Verbal Learning Test (HVLT) (n=7, 30%) [28–30, 35, 36, 40, 41], Trail Making Test (TMT) (n=4, 17%) [22, 29, 32, 35], Controlled Oral Word Association (COWA) (n=2, 9%) [29, 35], Digital Span (DS) (n=2, 9%) [29, 33], and Mini-Mental State Examination (MMSE) (n=2, 9%) [24, 37]. Three studies (13%) assessed the acute neurocognitive decline within the first 3 months after radiotherapy [27, 34, 39]. The remaining studies assessed long-term neurocognitive side effects with a minimum of 6 months and maximum of 12 years duration of follow-up.

Risk of bias and applicability

The results of the risk of bias and applicability assessment are shown in Table 2 and Figure 3. All models were judged to have a high risk of bias. The most common concerning issues were seen in analysis (domain 4), including lack of model validation and inappropriate or lack of handling missing data. Several models (n = 16, 70%) also had an unclear risk of bias in outcome assessment (domain 3) [19, 21, 23, 27, 29–35, 37–41]. This was due to lack of information on outcome assessment without knowledge of predictors.
| Study                              | ROB    | Applicability | Overall |
|------------------------------------|--------|---------------|---------|
|                                    | Participants | Predictors | Outcome | Analysis | Participants | Predictors | Outcome | ROB | Applicability |
| **Primary brain tumors**           |         |               |         |
| Gregor et al. (1996)               | -       | +            | ?       | -        | -            | +         | +       | -   | -               |
| Blay et al. (1998)                 | -       | -            | -       | -        | +            | +         | -       | -   | -               |
| Klein et al. (2002)                | +       | +            | ?       | -        | +            | +         | +       | -   | +               |
| Kaleita et al. (2004)              | +       | +            | +       | -        | -            | +         | -       | -   | -               |
| Van Beek et al. (2007)             | +       | +            | ?       | -        | +            | -         | +       | -   | -               |
| Wang et al. (2010)                 | +       | ?            | -       | -        | +            | -         | +       | -   | -               |
| Starke et al. (2011)               | -       | ?            | -       | -        | +            | +         | -       | -   | -               |
| Gondi et al. (2012)                | +       | -            | -       | -        | -            | +         | +       | -   | -               |
| Kangas et al. (2012)               | +       | ?            | ?       | -        | +            | -         | -       | -   | -               |
| Chapman et al. (2016)              | -       | -            | -       | -        | -            | +         | +       | -   | -               |
| Wong et al. (2019)                 | +       | ?            | ?       | -        | +            | +         | +       | -   | +               |
| Gui et al. (2020)                  | +       | +            | ?       | -        | +            | +         | +       | -   | +               |
| Dutz et al. (2020)                 | +       | -            | ?       | -        | -            | +         | +       | -   | -               |
| Tibbs et al. (2020)                | +       | -            | ?       | -        | +            | -         | +       | -   | -               |
| Zamanipoor et al. (2021)           | +       | -            | ?       | -        | +            | +         | +       | -   | +               |
| Langegard et al. (2021)            | -       | +            | ?       | -        | -            | +         | -       | -   | -               |
| **Secondary brain tumors**         |         |               |         |
| Wolfson et al. (2011)              | +       | +            | ?       | -        | +            | +         | +       | -   | +               |
| Gondi et al. (2013)                | +       | +            | -       | -        | +            | +         | +       | -   | +               |
| Nakazaki et al. (2013)             | +       | ?            | ?       | -        | +            | +         | +       | -   | +               |
| Yamamoto et al. (2017)             | -       | ?            | ?       | -        | +            | +         | +       | -   | +               |
| Chen et al. (2017)                 | +       | +            | ?       | -        | -            | +         | -       | -   | -               |
| Gui et al. (2019)                  | +       | -            | ?       | -        | +            | -         | +       | -   | -               |
| Brown et al. (2020)                | +       | -            | ?       | -        | +            | -         | +       | -   | -               |

**Abbreviation:** ROB, Risk of bias.

+ indicates low ROB/low concern regarding applicability;
- indicates high ROB/high concern regarding applicability;
? indicates unclear ROB/unclear concern regarding applicability.

Eight models received a low score for concerns about applicability, which indicates that they are well aligned with the review question [21, 29, 30, 33, 35–38]. The remaining models had high score for concerns about applicability. This was mostly due to concerns about applicability of the participants (domain 1), which reflects the use of ungeneralizable patient populations (e.g., secondary analysis of clinical trials).

**Discussion**

Page 7/13
This review summarized and evaluated 23 identified prediction models for neurocognitive decline after radiotherapy in patients with primary or metastatic brain tumors. The following risk factors were entered into at least two prediction models: age, tumor location, radiation dose to hippocampus, education level, baseline neurocognitive score, tumor type, size/volume of brain tumor(s), baseline depression/anxiety score, and type of radiotherapy (whole brain vs. focal). Although, many scholars have put substantial effort in developing prediction models for radiation-induced neurocognitive decline, the overall results are unsatisfactory. According to PROBAST, none of the models were judged to be at low risk of bias mainly due to limitations in modeling methodology.

The plethora of instruments measuring neurocognitive function is heartening. However, in the field of machine learning this negatively affects the comparability and reusability of the prediction models. There are a variety of aspects regarding the domains of instrument, how they are measured, and when specific neurocognitive functions are elicited [42]. Moreover, most of the used instruments have been developed to screen cognitive dysfunctions (e.g., dementia) in healthy elderly subjects without further adaptation and psychometric evaluation in patients with brain tumors [43]. This review clearly shows the gap in measuring the neurocognitive outcomes. Developing a standardized multidimensional instrument accompanied by an administration protocol would be beneficial toward developing a reliable prediction model.

A small number of significant predictors in prediction models (median=2) as well as the exclusion of four studies due to lack of significant predictors in multivariate analysis may imply that researchers need to follow a more systematic method for predictor selection before modeling. Although there is no recommended approach for selecting candidate predictors, using existing data in the literature in addition to a-priori knowledge of experts solicited from focus group discussions can be a solution to consider more predictive risk factors. The identified predictors in this review can be used as a potential set of predictors in future models.

Recent studies have documented deleterious associations between radiation dose to brain substructures and neurocognitive score in both pediatric and adult patients [44–48]. This is in line with the significant predictive power of radiation dose to the hippocampus, subventricular zone, and cerebellum in the available prediction models. This may provide important information about the radiation tolerance of the sub-volumes. In particular, it has been shown that equivalent doses of 2 Gy fractions to 40% of the hippocampus greater than 7.3 Gy is implicated in memory and learning impairments [26, 49]. Although current evidence on region-specific neurocognitive decline is limited, it is potentially an interesting trend for future model development studies.

In terms of the geographical distribution of the prediction models, all models were developed in countries with high human development index where early detection rate is likely higher than in developing countries [50]. Prediction models tailored to the population in less developed countries are needed before generalization and applications in clinical use.

About 26%, 35%, and 26% of the models had a high ROB in the participant, predictor, and outcome domains, respectively. However, high ROB in the analysis domain was observed in all prediction models. Two severe deficiencies in statistical analysis were rated as high risk in the majority of studies. The first deficiency was a lack of performance assessment. Prior to applying any of these prediction models into clinical practice, clinicians need to carefully consider the predictive performance of the models in different populations. Use in clinical practice can only be considered if the performance in the local clinical population is satisfactory. The second deficiency was lack of information on handling missing data. The majority of studies did not describe the method they used to manage missing data (removing subjects, single, or multiple imputation).

About 70% (n=16) of the models used easily-obtainable predictors, which would increase their applicability to clinical practice. It is reasonable that a combination of biomarkers and baseline neurocognitive scores would improve the predictive performance of the prediction models. However, prediction models including these variables were identified as high risk in applicability since these predictors are not routinely measured in daily practice. Another high concern regarding the applicability was due to an inappropriate data source. Developing a prediction model using data which have been collected during a clinical trial may not be generalizable to the intended target population.

The following limitations should be declared: First, only English studies were included. Second, studies in non-peer reviewed literature (e.g., conference proceedings or research reports) were not considered. Third, quantitative synthesis of the effect estimates was not conducted due to the heterogeneity of outcomes.

In conclusion, 23 prediction models are available to estimate the risk of neurocognitive decline after radiotherapy in patients with primary or secondary brain tumors. The models present substantial heterogeneity in terms of outcome assessment. Moreover, the existing models were judged to have a relatively high risk of bias, with the leading limitation of lacking internal/external validation and also deficiencies in the statistical methodology for model development. For future studies it is important to carefully choose a set of candidate predictors including radiation dose to uniformly delineated brain substructures.

**Declarations**

**Funding:** The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

**Conflict of Interest:** The authors declare that they have no relevant financial or non-financial conflict of interest.

**Ethical approval:** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent:** This is a systematic review study. No informed consent is needed.

**Data availability:** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Author contributions:** All authors contributed to the study conception and design. Material preparation, data extraction, and analysis were performed by Fariba Tohidinezhad and Dario Di Perri. Interpretation of the results was performed by Catharina M.L. Zegers, Jeanette Dijkstra, Monique Anten, Andre Dekker, Wouter
References

1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442
2. Sacks P, Rahman M (2020) Epidemiology of Brain Metastases. Neurosurg Clin N Am 31:481–488. https://doi.org/10.1016/j.nec.2020.06.001
3. Grunert M, Kassubek R, Danz B, et al (2018) Radiation and Brain Tumors: An Overview. Crit Rev Oncog 23:119–138. https://doi.org/10.1615/CritRevOncog.2018025927
4. Tanguturi SK, Alexander BM (2018) Neurologic Complications of Radiation Therapy. Neurol Clin 36:599–625. https://doi.org/10.1016/j.ncl.2018.04.012
5. Pazzaglia S, Briganti G, Mancuso M, Saran A (2020) Neurocognitive Decline Following Radiotherapy: Mechanisms and Therapeutic Implications. Cancers (Basel) 12:146. https://doi.org/10.3390/cancers12010146
6. Makale MT, McDonald CR, Hattangadi-GLuth JA, Kesari S (2017) Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol 13:52–64. https://doi.org/10.1038/nrneurol.2016.185
7. Mcuff SGR, Taich ZJ, Lawson JD, et al (2013) Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry 84:1384–1391. https://doi.org/10.1136/jnnp-2013-305166
8. Michaelidesová A, Konířová J, Bartůněk P, Zíková M (2019) Effects of Radiation Therapy on Neural Stem Cells. Genes (Basel) 10:E640. https://doi.org/10.3390genes10090640
9. Scaringi C, Agolli L, Minniti G (2018) Technical Advances in Radiation Therapy for Brain Tumors. Anticancer Res 38:6041–6045. https://doi.org/10.21873/anticancer.12954
10. Weber DC, Lim PS, Tran S, et al (2020) Proton therapy for brain tumours in the area of evidence-based medicine. Br J Radiol 93:20190237. https://doi.org/10.1259/bjr.20190237
11. Chen L (2020) Overview of clinical prediction models. Ann Transl Med 8:71. https://doi.org/10.21037/atm.2019.11.121
12. Chowdhury MZI, Turin TC (2020) Precision health through prediction modelling: factors to consider before implementing a prediction model in clinical practice. J Prim Health Care 12:3–9. https://doi.org/10.1071/HC19087
13. Gu H-Q, Liu C (2020) Clinical prediction models: evaluation matters. Ann Transl Med 8:72. https://doi.org/10.21037/atm.2019.11.143
14. van Grinsven EE, Nagtegaal SHJ, Verhoeff JJC, van Zandvoort MJE (2021) The Impact of Stereotactic or Whole Brain Radiotherapy on Neurocognitive Functioning in Adult Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Oncol Res Treat 1–15. https://doi.org/10.1159/000518848
15. Scoccianti S, Detti B, Cipressi S, et al (2012) Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol 108:291–308. https://doi.org/10.1007/s11060-012-0821-8
16. Geersing G-J, Bouwmeester W, Zuithoff P, et al (2012) Search Filters for Finding Prognostic and Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. PLoS One 7:e32844. https://doi.org/10.1371/journal.pone.0032844
17. Moons KGM, de Groot JAH, Bouwmeester W, et al (2014) Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. PLoS Med 11:e1001744. https://doi.org/10.1371/journal.pmed.1001744
18. Moons KGM, Wolff RF, Riley RD, et al (2019) PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. Ann Intern Med 170:W1–W33. https://doi.org/10.3390/cancers10090640
19. Gregor A, Cull A, Traynor E, et al (1996) Neuropsychometric evaluation of long-term survivors of adult brain tumours: relation with tumour and treatment parameters. Radiother Oncol 41:55–59. https://doi.org/10.1016/s0167-8140(96)91782-x
20. Blay JY, Conroy T, Chevreau C, et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864–871. https://doi.org/10.1200/JCO.1998.16.3.864
21. Klein M, Heimans JJ, Aaronson NK, et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368. https://doi.org/10.1016/s0140-6736(02)11392-5
22. Kaleita TA, Willschik CK, Cloughesy TF, et al (2004) Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol 67:245–253. https://doi.org/10.1023/b:neon.000021900.29176.58
23. van Beek AP, van den Berg ACM, van den Berg LM, et al (2007) Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys 68:986–991. https://doi.org/10.1016/j.ijrobp.2007.01.017
24. Wagner C, Caimcros G, Shaw E, et al (2010) Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys 77:662–669. https://doi.org/10.1016/j.ijrobp.2009.06.004
25. Starke RM, Nguyen JH, Rainey J, et al (2011) Gamma Knife surgery of meningiomas located in the posterior fossa: factors predictive of outcome and remission. J Neurosurg 114:1399–1409. https://doi.org/10.3171/2010.11.JNS101193
26. Gondi V, Hermann BP, Mehta MP, Tomé WA (2012) Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 83:e487-493. https://doi.org/10.1016/j.ijrobp.2011.10.021
27. Kangas M, Tate RL, Williams JR, Smee RI (2012) The effects of radiotherapy on psychosocial and cognitive functioning in adults with a primary brain tumor: a prospective evaluation. Neuro Oncol 14:1485–1502. https://doi.org/10.1093/neuonc/nos244
28. Chapman CH, Zhu T, Nazem-Zadeh M, et al (2016) Diffusion tensor imaging predicts cognitive function change following partial brain radiotherapy for low-grade and benign tumors. Radioter Oncol 120:234–240. https://doi.org/10.1016/j.radonc.2016.06.021
29. Wong SS, Case LD, Avis NE, et al (2019) Cognitive functioning following brain irradiation as part of cancer treatment: Characterizing better cognitive performance. Psychooncology 28:2166–2173. https://doi.org/10.1002/pon.5202
30. Gui C, Vannorsdall TD, Kleinberg LR, et al (2020) A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma. Neurosurgery 87:E31–E40. https://doi.org/10.1093/neuros/nyaa107
31. Dutz A, Agoli L, Bütof R, et al (2020) Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. Radiother Oncol 143:108–116. https://doi.org/10.1016/j.radonc.2019.12.024
32. Tibbs MD, Huynh-Le M-P, Reyes A, et al (2020) Longitudinal Analysis of Depression and Anxiety Symptoms as Independent Predictors of Neurocognitive Function in Primary Brain Tumor Patients. Int J Radiat Oncol Biol Phys 108:1229–1239. https://doi.org/10.1016/j.ijrobp.2020.07.002
33. Zamanipoor Najafabadi AH, van der Meer PB, Boele FW, et al (2021) Determinants and predictors for the long-term disease burden of intracranial meningioma patients. J Neurooncol 151:201–210. https://doi.org/10.1007/s11060-020-03650-1
34. Langegård U, Fransson P, Bjork-Eriksson T, et al (2021) Health-related quality of life in patients with primary brain tumors during and three months after treatment with proton beam therapy. Tech Innov Patient Support Radiat Oncol 17:5–17. https://doi.org/10.1016/j.tipso.2021.01.004
35. Wolfson AH, Bae K, Komaki R, et al (2011) Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:77–84. https://doi.org/10.1016/j.ijrobp.2010.05.013
36. Gondi V, Paulus R, Bruner DW, et al (2013) Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys 86:656–664. https://doi.org/10.1016/j.ijrobp.2013.02.033
37. Nakazaki K, Kano H (2013) Evaluation of mini-mental status examination score after gamma knife radiosurgery as the first radiation treatment for brain metastases. J Neurooncol 112:421–425. https://doi.org/10.1007/s11060-013-1071-0
38. Yamamoto M, Serizawa T, Higuchi Y, et al (2017) A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys 99:31–40. https://doi.org/10.1016/j.ijrobp.2017.04.037
39. Chen L, Shen C, Redmond KJ, et al (2017) Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. Int J Radiat Oncol Biol Phys 98:939–947. https://doi.org/10.1016/j.ijrobp.2017.02.031
40. Gui C, Chintalapati N, Hales RK, et al (2019) A prospective evaluation of whole brain volume loss and neurocognitive decline following hippocampal-sparing prophylactic cranial irradiation for limited-stage small-cell lung cancer. J Neurooncol 144:351–358. https://doi.org/10.1007/s11060-019-03235-7
41. Brown PD, Gondi V, Pugh S, et al (2020) Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38:1019–1029. https://doi.org/10.1200/JCO.19.00639
42. Cullen B, O’Neill B, Evans JJ, et al (2007) A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry 78:790–799. https://doi.org/10.1136/jnnp.2006.095414
43. Rasmussen DX, Bylsma FW, Brandt J (1995) Stability of performance on the Hopkins Verbal Learning Test. Arch Clin Neuropsychol 10:21–26
44. Haldbo-Classen L, Amidi A, Lukacova S, et al (2020) Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours. Radiother Oncol 148:1–7. https://doi.org/10.1016/j.radonc.2020.03.023
45. Toussaint L, Indelicato DJ, Stokkevåg CH, et al (2019) Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. Acta Oncol 58:1457–1462. https://doi.org/10.1080/0284186X.2019.1629014
46. Rodríguez de Dios N, Couñago F, Murcia-Mejía M, et al (2021) Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal-sparing prophylactic cranial irradiation for limited-stage small-cell lung cancer. J Neurooncol 144:351–358. https://doi.org/10.1007/s11060-019-03235-7
47. Gondi V, Tomé WA, Mehta MP (2010) Why avoid the hippocampus? A comprehensive review. Radiother Oncol 97:370–376. https://doi.org/10.1016/j.radonc.2010.09.013
48. Khazaee Z, Goodarzi E, Borhaninejad V, et al (2020) The association between incidence and mortality of brain cancer and human development index (HDI): an ecological study. BMC Public Health 20:1696. https://doi.org/10.1186/s12889-020-09838-4
Figure 1

PRISMA flow diagram for inclusion and exclusion of studies
Figure 2

Frequency of candidate and significant predictors in prediction models for radiation-induced neurocognitive decline in patients with primary or secondary brain tumors. Abbreviations: CT, Chemotherapy; FACT-G, Functional Assessment of Cancer Therapy-General; PCI, Prophylactic Cranial Irradiation; RT, Radiotherapy; SVZ, Subventricular Zone; WBRT, Whole brain RT.

| Predictor                      | Primary brain tumors | Secondary brain tumors |
|-------------------------------|----------------------|------------------------|
| Patient                       |                      |                        |
| Age                           | 7411                 | 34                     |
| Gender                        |                      |                        |
| Education level               |                      |                        |
| Marital status                |                      |                        |
| Performance status            | 1123                 | 1001                   |
| Prognostic class              | 011                  | 012                    |
| Endocrine disorder            | 101                  | 101                    |
| Baseline comorbidity score    |                      |                        |
| Baseline fatigue              | 101                  | 01                    |
| Baseline Pain                 | 011                  | 01                    |
| Baseline depression/anxiety   |                      |                        |
| Baseline neurocognitive score |                      |                        |
| Baseline FACT-G/brain         |                      |                        |
| Baseline social support       |                      |                        |
| Cancer                        |                      |                        |
| Tumor type                    | 235                  | 213                   |
| Tumor location                | 505                  | 215                   |
| Size/volume of the brain tumor(s) |                | 022                  |
| Extracranial metastasis       |                      |                        |
| Treatment                     |                      |                        |
| Use of RT                     | 145                  | 213                   |
| Type of RT (WBRT vs. focal RT) |                      |                        |
| Use of PC                     | 011                  | 011                   |
| Prescribed radiation dose     | 134                  | 022                   |
| Radiation dose to brain substructures |          | 022                  |
| Radiation dose to the brain   | 022                  | 303                   |
| Radiation dose to the hippocampus |                | 101                  |
| Radiation dose to the SVZ     |                      |                        |
| Radiation dose to the cerebellum |                | 101                  |
| Reirradiation                 | 011                  | 011                   |
| Post-RT reduction in brain volume |                |                      |
| Association of RT and CT      | 112                  | 033                   |
| Use of surgery                | 011                  | 022                   |
| Type of surgery               |                      |                        |
| Reoperation                   |                      |                        |
| Medication                    |                      |                        |
| Antiepileptic drug            | 101                  | 011                   |
| Sedative drug                 |                      |                        |
| Other                         |                      |                        |
| Duration of follow-up         | 178                  | 112                   |

Significant: ☐
Non-significant: ☑
Summary of risk of bias (top) and applicability (bottom) according to the Prediction model Risk Of Bias Assessment

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryMaterialS1.pdf